Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Operations (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Cash from Operations for 10 consecutive years, with 25389000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 34.73% to 25389000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 115675000.0, a 1.58% decrease, with the full-year FY2025 number at 115675000.0, down 1.58% from a year prior.
  • Cash from Operations was 25389000.0 for Q4 2025 at Rhythm Pharmaceuticals, up from 26622000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 18845000.0 in Q4 2024 to a low of 53632000.0 in Q1 2022.
  • A 5-year average of 34257100.0 and a median of 33765500.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 59.95% in 2022, then surged 37.75% in 2023.
  • Rhythm Pharmaceuticals' Cash from Operations stood at 40472000.0 in 2021, then rose by 15.99% to 34000000.0 in 2022, then increased by 13.58% to 29383000.0 in 2023, then soared by 35.86% to 18845000.0 in 2024, then crashed by 34.73% to 25389000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Cash from Operations are 25389000.0 (Q4 2025), 26622000.0 (Q3 2025), and 23313000.0 (Q2 2025).